RxDoctor Payments Data

Salimah Chagani

Family · Duluth, GANPI 1437608684

Payments from drug & device makers

$5,323in general payments, 2019–2025

Across 237 payments — averaging $22.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$729
  • Lilly USA, LLC$515
  • Novo Nordisk$416
  • Bayer$353
  • Medtronic$270
  • Xeris Pharmaceuticals, Inc.$238
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$5,29199%
  • Education$321%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,323 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$158,247
Medicare patients
160
Services billed
6,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide189$296,278
OzempicSemaglutide169$254,516
JardianceEmpagliflozin132$162,059
TrulicityDulaglutide98$137,858
FarxigaDapagliflozin Propanediol69$92,929
Tresiba Flextouch U-200Insulin Degludec68$90,556
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/727$43,530
KerendiaFinerenone42$42,974
Humalog Kwikpen U-200Insulin Lispro11$40,336
JanuviaSitagliptin Phosphate26$29,099
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog43$28,627
Tresiba Flextouch U-100Insulin Degludec28$26,887
Novolog FlexpenInsulin Aspart56$18,260
NexlizetBempedoic Acid/Ezetimibe17$17,478
Repatha SureclickEvolocumab16$17,401

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Lyumjev, Humalog$515$458,555351 claims
Novo NordiskOzempic, Novolog$416$271,916199 claims
Boehringer IngelheimJardiance, Tradjenta$93$175,021150 claims
AstraZenecaFarxiga$172$92,92969 claims
BayerKerendia$353$42,97442 claims
MerckJanuvia$55$29,09926 claims
Esperion Therapeutics, Inc.Nexlizet$53$17,47817 claims
AbbVieSynthroid$99$13,489143 claims
Cequr CorporationCequr Simplicity$61$7,48517 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$56$2,327199 claims
PfizerLevoxyl$47$94120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.

Other family in Duluth

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →